Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature

BACKGROUND: Sintilimab is an immune checkpoint inhibitor (ICI). It can induce immune-related Adverse Events (irAEs). Severe adverse skin reactions are rare, but the mortality rate is high. We report the first case of successful treatment of adverse skin reactions using traditional Chinese medicine (...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Juan, Ma, Na, Qiao, Wei-Li, Liu, Ke-Qin, Liu, Dai-Wei, Wang, Yu, Qiao, Ting-Ting, Hao, Xiu-Qing, Zheng, Mao-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843412/
https://www.ncbi.nlm.nih.gov/pubmed/36660611
http://dx.doi.org/10.21037/atm-22-5925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843412/
https://www.ncbi.nlm.nih.gov/pubmed/36660611
http://dx.doi.org/10.21037/atm-22-5925

Ejemplares similares